TECHNOLOGIES. Bitdefender informs you that in certain programs or products it may use data collection technology to collect technical information (including suspect files), to improve the products, to provide related services, to adapt them to the latest industry trends and to prevent the unlicensed or illegal use of the product or the damages resulting from the malware products. You accept that Bitdefender may use such information as part of the services provided in relation to the product and to prevent and stop the malware programs running on your device. By accepting this Agreement, You acknowledge and agree that the security technology used can scan the traffic in an impersonal mode to detect the malware and to prevent the damages resulting from the malware products. You acknowledge and accept that Bitdefender may provide updates or additions to the program or product which automatically download to your device. By accepting this Agreement, You agree that some of the executable files considered potentially harmful, may be submitted to Bitdefender servers for the purpose of being scanned. Bitdefender reserves the right to collect certain information from the computer on which it is installed, depending on the modules and services You have activated in your Bitdefender Solution. Such information may pertain to potential security risks as well as to URLs of websites visited that the Bitdefender Solution and Services deems potentially fraudulent. The URLs could contain personally identifiable information that a potentially fraudulent website is attempting to obtain without Your permission. As such, You agree that certain Product modules, services and components may collect pieces of data from your systems for the purpose of evaluating and improving the ability of Bitdefender’s products to detect malicious behavior, potentially fraudulent websites and other Internet security risks. Bitdefender also employs proprietary Cloud technologies to perform scanning on certain URLs, files or emails submitted from your systems.
TECHNOLOGIES. The collaboration will leverage Cytokinetics' proprietary platform, Cytometrix(TM) cellular phenotyping technologies, which are routinely utilized in Cytokinetics' screening processes to analyze both on-target and off-target effects of candidate compounds. Cytometrix(TM) cellular phenotyping technologies utilize cell-based assays to create digital phenotypic profiles ("fingerprints") representative of diverse molecular mechanisms of drug action. Cytometrix(TM) fingerprints detail information on the potency and specificity of a compound or drug-related toxicities. Cytokinetics presently employs Cytometrix(TM) cellular phenotyping technologies to eliminate compounds of mixed mechanism, allowing the company to focus its medicinal chemistry and pharmacology resources more selectively on higher quality chemical series. This collaboration with AstraZeneca is designed to develop a new Cytometrix(TM) technologies application called the Cytometrix(TM) Hepatotoxicity Module for the in vitro prediction of hepatotoxicities downstream of screening. - more - ABOUT CYTOKINETICS Founded in 1998 and privately held, Cytokinetics is dedicated to the discovery, development and commercialization of a novel class of therapeutics resulting from its leadership position in the emerging field of cytoskeletal pharmacology. The cytoskeleton is a complex, dynamic framework that impacts all aspects of cell function including cell division, cell motility, intracellular transport, muscle contractility and regulation of cellular organization. Cytokinetics' R&D efforts aim to address pharmaceutical needs in cancer, cardiovascular and infectious diseases and feature proprietary Cytometrix(TM) cellular phenotyping technologies designed to industrialize cell biology for increased speed and productivity in drug discovery and development. Cytokinetics and GlaxoSmithKline have entered into a broad strategic collaboration to discover, develop and commercialize novel small molecule therapeutics targeting mitotic kinesins for applications in the treatment of cancer and other diseases. Cytokinetics and GlaxoSmithKline are conducting Phase I studies with the first novel anti-cancer drug candidate emerging from the collaboration and intend to expand clinical development upon completion of these studies. Additional information about Cytokinetics can be obtained at www.cytokinetics.com. ABOUT ASTRAZENECA AstraZeneca is a major inxxxxxxxxxxx xxxxxxxxre business engaged in the research, development, manuf...
TECHNOLOGIES. Due to the fact that the frequency coordination situation of GSM vs. GSM has already been regulated, the following coordination situations are regulated in this Technical Arrangement: • GSM system vs. broadband systems • broadband systems vs. broadband systems With regard to these relationships between the narrow band GSM and the broadband systems and between broadband systems, the applied principles are the following:
TECHNOLOGIES. Annex 8(a) hereto correctly describes technologies used in the Business included in the Contributed Assets (the "TECHNOLOGIES"), which AL1 owns or has licenses to.
TECHNOLOGIES. Flagship has also adopted a series of cutting edge technologies that enable us to continually monitor the quality of service we’re providing: • Biometric time keeping systems • Restroom FOB tracking system • Proprietary Inspection System • Work Order and Periodic Work Order Systems.
TECHNOLOGIES. Subject to the terms and conditions of this Agreement, at the Closing, Seller will sell, convey and transfer to Buyer, and Buyer will purchase from Seller, the following Technologies (the "Technologies"): All of Seller's right, title and interest to the Mariah Internet Protocol Telecomputing Project, the MindWalker Series, the Crayon Crawler Browser, the Spirit 32 Voice Mailer and all of the tradenames and copyrights associated with the names "Crayon Crawler," "Mindwalker" and "Mariah." Buyer takes said Technologies "as is" without warranty of any kind either expressed or implied.
TECHNOLOGIES. 2.1.1 General Packet Radio Service (“GPRS”) GPRS is a specification for data transfer on TDMA and GSM networks with speeds of up to one hundred seven (107) Kbps. GPRS has wireless data coverage in most major metropolitan areas.
TECHNOLOGIES. Only solar electric photovoltaic (PV) facilities qualify as Eligible Facilities. The Seller is responsible for registering and maintaining their Facility as RPS compliant with the California Energy Commission (CEC). Refer to the CEC RPS Eligibility Guidebook1 for the latest certification requirements. QUALIFIED FACILITY COMPONENTS Only photovoltaic modules that are certified by a nationally recognized testing laboratory are eligible.2 All photovoltaic modules must be certified as meeting the requirements of the Underwriters Laboratory Standard (UL) 1703. For custom photovoltaic modules not certified by UL 1703, parties may seek certification by the Los Angeles Department of Building and Safety Materials Test Lab (xxxx://xxxxx.xxx). Facilities will not be approved by LADWP inspectors until proof of certification is received by LADWP. All inverters must be certified by a nationally recognized testing laboratory for safe operation and must be certified as meeting the requirements of UL 1741. LADWP reserves the right to adopt additional codes, standards, and conditions, prior to execution, at its sole discretion. 1 The CEC RPS Eligibility Guidebook can be found at: xxxx://xxx.xxxxxx.xx.xxx/renewables/documents/ 2 The CEC maintains a list of certified modules that can be obtained from the CEC website at: xxxx://xxx.xxxxxxxxxxxxxxxxx.xx.xxx PARCEL LIMITATIONS The renewable generator(s) that constitutes the Facility shall be within the boundaries of one legal parcel, identified by Appendix D by Assessors Parcel Number (APN).
TECHNOLOGIES. (a) Phoenix shall supervise CLL employees who are technologists, marketing, or administrative personnel to ensure the ongoing provision of Vascular Laboratory Services, marketing services, and administrative services to CLL and CLL customers. Should CLL or its customers require services (whether clinical, marketing, or administrative or otherwise) beyond those services which are able to be provided by CLL employees, for reasons of volume, scheduling, vacations, on-call coverage, illness, training, or otherwise, then Phoenix shall use its best judgment and efforts to supply such additional services through Phoenix employees or through third-party contractors. Such additional services shall be paid by CLL at a cost equal to Phoenix's actual out-of-pocket expense associated with the Phoenix employee or third-party contractor. Phoenix warrants and represents that all clinical services will be performed by appropriately credentialed employees and third-part contractors. In the case of vascular technologists, all personnel will be either Registered Vascular Technologists or Registry eligible. In the case of echocardiographic technologists, all personnel shall be RDMS qualified in echocardiography. Phoenix shall ensure that all CLL clinical personnel are properly trained to meet all clinical requirements set forth by insurance carriers, Medicare, or third parties such as hospitals. In the event of a conflict between the selection of a Phoenix employee or a CLL employee to perform clinical services at a CLL Vascular Laboratory, Phoenix shall exercise the utmost in professional and commercial judgment to insure that CLL's interests are adequately represented at all times. Phoenix shall make ongoing staffing recommendations to CLL to ensure that CLL has adequate staff to deliver the Vascular Laboratory Services and other services to CLL customers. CLL, in its sole discretion, will have the final authority to implement such staffing recommendations, or not.
TECHNOLOGIES. All such inventions and copyrightable works that Consultant is obligated to disclose shall be and remain entirely the property of Company or its nominees, successors, or assigns. It is agreed that all copyrightable works and inventions are works made for hire and shall be the exclusive property of Company. Further, Consultant agrees to assign and hereby assigns to Company any rights he may have in such works. Such assignment includes any rights in the inventions and copyrightable works described in this Paragraph A that may have accrued to Consultant since October 1, 2003.
